Replies to post #89008 on Amarin Corp Plc (AMRN)

[Pyrrhonian]

Okay look, of course generics will appear higher tiered than their more expensive brand name. That's so obvious it's not worth talking about. Vascepa appears higher than Lovaza or generic L in exactly zero plans.

The only reason I even brought that up was in a small aside as to whether or not I would take Vas or Lov ever, and I would only do it if my TG counts were very high, and I would choose Lov (sure, generic is fine) over Vas, because of what I view as the added benefits of DHA. I then pointed out its always higher tiered than Vas (or at best equivalents) and so it would be easier to get coverage. That's not incorrect.

There really is nothing to argue about. You created it out of thin air.

Yes I'm sure they both require PA, at least as pertained our discussion. You said "United" had Lov as PA but not Vas. Page 12, both PA.

https://www.myuhc.com/content/myuhc/Member/Assets/Pdfs/100-16910_FS_3T_Adv_PDL_116_6.pdf

I have no more interest in talking about that, but respond how you wish.

VuBru could give a more educated answer (if he want), however do you think
- everybody has a primary care doc? Especially ex-US enrollees --HD

I really doubt s/he could. He's not a cardiologist or primary care physician. I wouldn't (personally) take a plastic surgeon's word for it either. Especially if they have little basic understanding of ischemia or cardiac tissue repair.

There is no way a patient like Whal, for instance, who was turned *away* from entering the study at that point because they were looking for those with a worse outlook, would just stop having their lipids evaluated for *years*. You can try and reason out of that however you like, you will only fool yourself.

If 5-10% of the patients in placebo arm dropped out because they realized they were just taking mineral oil, it may not alter blended event rates enough for another hike in sample size. Especially as they already did that once. And maybe one of the reasons (stated or not) that they did the last time is because placebo arm dropout was high.

The problem is with this particular kind of informed censoring, it's those with the highest stubborn TG counts, who must monitor them routinely (pancreatitis, etc.), who would be most likely to drop out of that arm. Watching your TGs go from 750 to 775 after 3 months would probably tell you exactly what was in that pill you take 4x a day, every day. These patients have higher MACE risk, but may be dropping out of p group, causing an imbalance of them in vas group. That would of course skew event rates in favor of p group.

Jmo

GL